clonal hematopoiesis of indeterminate potential (CHIP)

(iStock image)
January 8, 2026

Patients with clonal hematopoiesis have increased heart disease risk following cancer treatment 

Study supports the potential benefits of screening patients for CHIP before they undergo cancer treatment so they can be more closely monitored for heart complications.

By Tom Wilemon
(iStock image)
January 7, 2026

Study identifies potential target for blood cancer treatment, prevention

The findings could lead to new treatments for blood cancers, which kill an estimated 23,540 people in the United States every year.

By Bill Snyder
September 23, 2025

Seeds for Science

VICC Ambassador Grants have worldwide impact

By Jill Clendening
(iStock image)
June 23, 2025

Low blood cell counts drive cancer in explosive blood disorder: study

The analysis of genetic sequencing data from more than 34,000 people over a 17-year period by researchers at VUMC was published in eClinicalMedicine.

By Bill Snyder
(iStock image)
November 25, 2024

Potential treatment eyed for abnormal blood cell disorder

Research could lead to improved diagnosis and the first effective treatment for the disorder, called “clonal hematopoiesis of indeterminate potential,” or CHIP. 

By Bill Snyder
Graduate student Taralynn Mack, left, pipettes a sample while Alexander Bick, MD, graduate student Hannah Poisner, and Celestine Wanjalla, MD, PhD, look on.
June 4, 2024

Research raises hope for treating potentially lethal blood condition

Roughly 1 in 10 people over age 70 will develop CHIP, an explosive, clonal growth of abnormal blood cells that increases risk of blood cancers and death from cardiovascular, lung and liver disease.

By Bill Snyder
March 7, 2024

Blood mutations increase risk for acute kidney injury: study

A U.S.-Canadian research collaboration led by Vanderbilt University Medical Center has identified common, age-associated changes in the blood as a risk factor for acute kidney injury, which occurs in more than 1 in 5 hospitalized adults worldwide.
By Bill Snyder
May 18, 2023

New view of mutations informs disease risk, treatment response

A transcontinental research effort led by scientists from Vanderbilt University Medical Center and the University of Michigan has upended some long-standing assumptions about mutations — how often they occur, what causes them and what they do.
By Bill Snyder
April 12, 2023

Research identifies new target that may prevent blood cancer

An international coalition of biomedical researchers co-led by Vanderbilt's Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer.
By Bill Snyder
February 2, 2023

Researchers clarify role of blood cell mutations in disease

Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.
By Bill Snyder
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease
By Tom Wilemon